The abstract is read at the publisher; the summary is JClub's.
Monoallelic class 2 SMARCA4 alterations with preserved BRG1 expression in a phase I trial of PRT3789 showed clinical benefit, including one complete response.
- Why it matters: The clinical implications of different SMARCA4 alteration classes are not fully defined, limiting how patients might be selected for emerging BRM-targeted therapies.
- What they did: A pan-cancer analysis of 68,920 tumor-normal paired samples sequenced with MSK-IMPACT (2015–2023) characterized SMARCA4 mutation classes and linked them to allelic status, genomic complexity, and outcomes in platinum and immune checkpoint cohorts.
- The result: SMARCA4 alteration class and allelic status defined biologically and clinically distinct tumor subsets, supporting incorporating both into patient selection for BRM-targeted treatments.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.